The intra-abdominal visceral deposition of adipose tissue, which characterises upper body obesity, is a major contributor to the development of hypertension, glucose intolerance and hyperlipidaemia. Conversely, individuals with lower body obesity may have comparable amounts of adipose tissue but remain relatively free from the metabolic consequences of obesity. This raises an obvious questionÐare there particular weight reducing treatments which speci®cally target intra-abdominal fat?
Introduction
The intra-abdominal visceral deposition of adipose tissue, which characterises upper body obesity, is a major contributor to the development of hypertension, elevated plasma insulin concentrations with insulin resistance, diabetes mellitus and hyperlipidaemia. 1 Conversely, individuals with lower body obesity may have comparable amounts of adipose tissue but remain relatively free from these metabolic consequences of obesity. This raises two important questions: (1) why does intra-abdominal fat have such a detrimental in¯uence on metabolic function? (2) are there particular weight reducing treatments which speci®cally target intra-abdominal fat? This paper will address these questions.
Normal adipose tissue function
Fat tissue mass is dependent on the number and size of adipocytes. Adipocytes have the unique characteristic of being dominated by their contents of storage fats, triglycerides. The mass of triglycerides in an adipocyte is dependent on the balance between triglyceride in¯ux and mobilisation; the latter in the form of free fatty acids (FFA) and glycerol is regulated by metabolic processes under hormonal and nervous system control. 2 The body fat's stores are almost entirely in the form of triacylglycerol (TAG) in adipocytes. The process of fat mobilisation consists of hydrolysis of the stored TAG to release non-esteri®ed fatty acids (NEFA) into the circulation. The key enzyme is the intracellular TAG-lipase, hormone sensitive lipase (HSL). Lipolysis is stimulated by catecholamines acting via b-adenoceptors and certain hormones which increase the activity of adenylate cyclase in adipocytes leading to the formation of cyclic-AMP from ATP. 35 Dephosphorylation of HSL occurs when cyclic AMP concentrations falls. The main hormonal regulator of this is insulin, which lowers adipocyte cyclic AMP concentrations. 6 Catecholamines acting on a 2 -adrenoreceptors will also inhibit lipolysis. 7 In the postprandial state the enzyme lipoprotein lipase (LPL) in adipose tissue is activated by insulin and possibly also by some gastrointestinal peptide hormones. 8 LPL releases fatty acids which may be taken up into the tissue for esteri®cation and storage as TAG. The fatty acids released by LPL action are not all taken up by adipose tissue for storage with approximately 50% entering the systemic circulation. 9 This release of LPL-derived fatty acids is dependent upon the insulin response to the meal and the sensitivity of LPL activation to insulin and other hormones.
Regional distribution of body fat
The potential differences in FFA metabolism between lean and obese subjects may re¯ect the anti-lipolytic effectiveness of insulin in obesity, the relationship of FFA release to the amount of body fat and the lipolytic responsiveness of obese individuals to catecholamines. It is relevant that adipocytes from various body regions differ from one another in many respects. 10 The basal release of FFA from adipose tissue to meet lean body mass energy needs is greater in upper body obese women than obese women with lower body fat distribution and non-obese women. Differences in the ability of insulin to suppress lipolysis and of catecholamines to stimulate lipolysis also varies according to fat distribution. 11 In both men and women, the lipolytic response to noradrenaline, which acts via a 2 -and b-adrenoceptors (particularly b 3 ), is more marked in abdominal than gluteal or femoral tissues. 12, 13 Cortisol may also contribute to this enhanced lipolysis by further inhibiting the anti-lipolytic effect of insulin.
14 As a consequence more FFA is released into the portal system which, in turn, has a deleterious effect on insulin uptake by the liver and contributes to the increased hepatic gluconeogenesis observed in upper body obesity (Figure 1 ).
Androgens have a clear effect on adipose tissue metabolism; this includes enhancement of lipolytic sensitivity by expression of lipolytic b-adrenergic receptors via an androgenic receptor, which is positively autoregulated by testosterone. 15, 16 The density of androgen receptors, which are speci®c for androgens, varies in different adipose tissue regions with a higher density in intra-abdominal than subcutaneous depots in rats. 17 Indirect evidence suggests a higher density in central visceral fat in man compared to peripheral adipose tissue. 18 Testosterone, in the presence of growth hormone (GH) exerts a dramatic effect on the regulation of lipolysis by increasing the number of b-adrenoceptors through an action at the level of adenylate cyclase and protein kinase A and/or HSL. 15, 16, 19 Insulin secretion in obesity All forms of obesity are characterised by an elevated fasting plasma insulin and an exaggerated insulin response to an oral glucose load. 20 However, the overall fatness and the distribution of body fat in¯u-ence glucose metabolism through independent but additive mechanisms. Kissebah and colleagues 21 have demonstrated that increasing upper body obesity is accompanied by a progressive increase in the glucose and insulin response to an oral glucose challenge. They observed a positive correlation between increasing upper body obesity and a measure of insulin resistance (steady state plasma glucose, SSPG). After adjustment for the effects of overall fatness (% ideal body weight), upper body obesity remained independently correlated with SSPG suggesting that the location of body fat is an independent factor in¯uencing the degree of insulin sensitivity and, in turn, metabolic pro®le.
Measurement of portal plasma insulin levels (as a index of insulin secretion) show similar levels in upper body and lower body obesity but hepatic insulin extraction, both basally and during stimulation by intravenous or oral glucose, is reduced in upper body obesity. 22 As a consequence, post hepatic insulin delivery is increased in upper body obesity leading to more marked peripheral insulin concentrations. This, in turn, leads to peripheral insulin resistance ( Figure  1 ). Studies of insulin sensitivity and responsiveness of skeletal muscle and the relationship to overall glucose disposal in premenopausal women, with varying body fat distribution, have revealed a signi®cant decline as upper body fatness increases. 23 The effect of weight reduction
Weight reduction in subjects with upper body obesity has a marked effect on the regulation of lipolysis.
There is approximately a ®vefold increase in the sensitivity to noradrenaline with a speci®c effect on adrenoreceptor subtype with increased sensitivity to b 2 -receptors but no change in b 1 -or a 2 . 24 More recently a similar pattern of increased sensitivity has been reported for b 3 -adrenoreceptors. 13 Weight loss is accompanied by a decrease in circulating insulin levels and a fall in plasma noradrenaline. The bene®cial effects of these changes are a decrease in basal lipolysis (with decreased HSL function) and an increase in sensitivity to catecholamine stimulation of lipolysis. 9 Thus weight reduction appears to restore a more ef®cient regulation of lipolysis with less FFA being released at rest and lower catecholamine levels required for lipolysis activation.
The bene®cial action of weight reduction con®rms that many, if not all, of the deleterious events associated with upper body obesity are a consequence, rather than a cause, of excessive visceral adipose tissue. This justi®es the search for treatments which will speci®cally reduce intra-abdominal visceral fat.
Upper body vs lower body fatÐdoes any particular treatment speci®cally reduce abdominal visceral fat?
There is surprisingly little published information about the effect of treatment methods on intra-abdominal fat. Many papers allude to possible bene®ts of a speci®c treatment without providing supportive evidence. For the purpose of this review only published evidence which contains information about one or more of the following will be considered: measurement of intra-abdominal fat tissue volume using computerised axial tomography (CAT scan) or magnetic resonance imaging (MRI); serial measurements of waist circumference or waist to hip circumference ratio during weight loss and weight maintenance; demonstrable improvements in metabolic function with weight loss which are likely to have resulted from a reduction in abdominal visceral adipose tissue.
There are four possible treatment options for intraabdominal fat:
(1) Surgical removal (2) Dietary restriction (3) Physical activity and exercise training (4) Pharmacotherapy drugs with a speci®c action on intra-abdominal fat.
These options will be discussed in turn.
Surgical removal
In theory, surgical excision of upper body fat should be effective. In reality, neither liposuction (suction removal of subcutaneous fat) nor removal of an apron of abdominal fat (apronectomy) have any bene®cial effect on the metabolic alterations associated with upper body obesity. This is not surprising because such operative procedures remove subcutaneous and not deeper visceral fat. Moreover, in most circumstances, both techniques are followed by rapid replacement of the extracted adipose tissue with weight regain. There are no published reports which have examined the metabolic bene®ts of these procedures.
Gastric surgery: there are two alternative operative procedures which involve the stomach. Both proce- dures may result in substantial weight loss due to reduced energy intake providing suitable obese patients are selected for operation.
Gastric restriction techniques: gastroplasty techniques involve the fashioning of a proximal pouch of the stomach by vertical stapling, thereby restricting the gastric volume to approximately 15 mls. The opening of the pouch may be reinforced externally by a nylon mesh, fascia or te¯on. Vertical gastric banding (VBG) involves the external`pinching off' of the upper part of the stomach with a band usually made of dacron.
Malabsorption techniques: gastric bypass combined with a gastroplasty has gained popularity and is the most commonly employed surgical procedure in many centres. The procedure involves fashioning a pouch of up to 30 ml volume by stapling across the stomach and bringing up a limb of small intestine as a conduit for food, thus bypassing the distal stomach, duodenum and proximal jejunum.
Ef®cacy of gastric surgery as treatment for intraabdominal fat: Letiexhe and colleagues 25 have shown dramatic bene®ts on metabolic function in 12 severely obese patients following vertical banded gastroplasty. These patients experienced a mean weight loss of 31.4 kg with a mean reduction of BMI from 37.9±26.5 kg/m 2 . There was additionally a signi®cant decrease in waist to hip ratio from 0.83± 0.78 eight months after operation. Importantly, these physical changes were accompanied by marked improvements in metabolic function with signi®cant reductions in the plasma glucose and insulin responses during a frequently sampled intravenous glucose tolerance test but no signi®cant change in C-peptide levels ( Figure 1 ). The authors concluded that the improvements in insulin sensitivity probably re¯ected increased hepatic insulin extraction rather than alterations in peripheral tissue uptake: this is suggestive of a reduction in intra-abdominal visceral fat.
Sjostrom and colleagues 26 have shown a comparable amount of weight loss two years after gastric bypass. The initial ®ndings for the Swedish study, which is assessing the longer term bene®ts from obesity surgery (SOS), con®rm that substantial weight loss (approximately 30 kg) is associated at two years with 60% reduction in plasma insulin, 25% decrease in glucose and triglycerides and a 10% reduction in blood pressure. Furthermore, this degree of weight loss results in a 14 fold reduction in risk of developing diabetes and a 3±4 fold risk reduction for the development of hypertension, hypertriglyceridaemia and low HDL cholesterol levels. It should be emphasised that the profound weight loss experienced by the subjects resulted from a global decrease in body fat rather than a localised loss.
Dietary methods
A number of studies have examined whether dietary methods for weight reduction selectively reduce intraabdominal fat. Stallone et al 27 used CAT scans to measure the relative size of fat depots in three separate areas before and after substantial weight loss, induced by a six month programme of verylow-calorie diet and behaviour therapy. They studied 11 post-menopausal women who were at least 20 kg overweight (mean BMI 37 kg/m 2 ). The programme included three months of treatment by a 400±800 kcal/d diet, two months of a refeeding diet and one month of a balanced diet (1200±1500 kcal). Fat depots were measured at the level of the fourth lumbar vertebra (L4), acetabular roof of the pelvis and at the midportion of the thigh. The size of the abdominal visceral fat depot was assessed at the level of L4. The most important ®nding from this study was that a mean weight loss of 18.8 kg (14.8 kg of fat) produced a 33% reduction in abdominal visceral fat. The decrease in visceral fat was highly correlated with total pre-treatment body weight and fat, and the reduction in body fat accounted for 46% of the variance in the change in visceral fat. Details of the results at six months are shown in Table 1 . These preliminary results indicate the ability of obese post-menopausal women, with large visceral fat depots, to lose large amounts of visceral fat with weight reduction. An additional noteworthy ®nding from the study was that total fat loss from the abdominal and pelvic regions were very similar (35.3 and 31.5% respectively). Moreover, there was no signi®cant difference in fat loss between intra-abdominal and subcutaneous depots or intrapelvic or subcutaneous depots suggesting dietary restriction results in an overall reduction in body fat rather than a speci®c loss from a particular site.
It seems likely that a similar situation also applies to men. The GutBuster`weight loss' programme in eastern Australia has targeted overweight men. 28 This programme used the results of research which determined the attitudes of working men to the use of health resources. The ®ndings from the survey suggested that any male weight control initiative had to be non-threatening and include non-disruptive changes to lifestyle in order to be successful. The devised programme comprised of six initial sessions on sensible eating (with emphasis on low fat and increased dietary ®bre), behavioural changes, increased physical activity and reduced alcohol con- ) 131 (15) 7 (7) sumption. This was followed by an`advanced', or more detailed, course at the request of a number of men. The goal for the programme was a decrease in waist circumference as distinct from a reduction of weight. All the groups involved in the initial programme achieved an average waist loss of greater than 1% per week. Moreover, waist sizes were signi®cantly less after two years averaging a 6% loss for the group as a whole. This equated to an average weight loss of 5.5 kg. Those who additionally undertook thè advanced' course had signi®cantly greater waist reduction at one year (average 10% compared to 4% in initial group). The authors concluded that measuring reductions in waist size may prove to be more feasible than measuring weight loss as a method to achieve longer term dietary adherence. The results also con®rm simple dietary methods to be a practical option for tackling intra-abdominal fat in men. Serial measurements in a large group of subjects (3753 black and white men and women) over ®ve years have con®rmed that weight gain and weight loss are associated with changes in the waist to hip ratio (WHR) in both genders. 29 Those in the study, who increased weight, increased their WHR while WHR was reduced in those who lost weight. Men had greater increases in WHR per kg weight gain while women had greater reductions in WHR per kg of weight loss. In general, a 1 kg loss in men was accompanied by 0.70 cm decrease in waist but no signi®cant change in the hip circumference; in women, an identical loss in weight resulted in 0.8 cm waist reduction and 0.83 cm decrease in hips. This belies the common belief that women have more dif®culty than men in reducing waist and hip circumferences with weight loss.
Physical activity and exercise training
Exercise produces fat loss in obese and lean subjects, but the losses rarely exceed 5% of body weight. Exercise increases lean body mass and reduces the waist to hip ratio. The weight loss through exercise, although generally small, exceeds that predicted if direct energy expenditure calculations are performed. It is likely that exercise has complex effects on the body which are not fully explained by the energy expended in physical activity. It has been proposed that the two processes most likely to be affected by exercise are appetite and basal metabolism. 30 Regular exercise results in reduction in blood pressure both in association with or independently of weight loss, and results in an improvement in atherogenic lipid pro®les. 31 A reduction in triglycerides and low-density lipoprotein cholesterol and elevation of high-density lipoprotein cholesterol have been reported with exercise and physical training in obese patients. 32 Exercise also has bene®cial effects on glucose metabolism and skeletal muscle sensitivity to insulin. These metabolic improvements suggest that exercise may have speci®c effects upon intra-abdominal adipocyte function but there is presently no objective evidence in support of this. Regular exercise should be considered a priority for any treatment programme devised to tackle intra-abdominal fat. However, persuading an obese persons to take part in long term exercise programmes and to maintain exercise as part of daily routine is not easy. It is not necessary to increase maximal oxygen uptake in the obese to derive bene®t from exercise: metabolic evidence of ®tness is achieved with less vigorous exercise such as increased walking distances and swimming. The risks from exercise are not great providing it is introduced gradually and other complications such as osteoarthritis and ischaemic heart disease are taken into account.
33,34

Pharmacotherapy
There have been a number of reports of the use of certain hormones and centrally acting serotoninergic agents for the treatment of patients with upper body obesity. There are no publications speci®cally about the use of ephedrine, xanthine derivatives such as caffeine or b 3 -agonist as treatment for intra-abdominal fat.
Hormonal treatment: there has long been an interest in the use of hormones to treat obesity on the premise that the condition results from a hormonal de®ciency. Obesity per se does not result from an endocrine disorder and it is therefore not appropriate to use hormone therapy as a means of reducing weight. Human chorionic gonadotrophin (HCG) and thyroxine are not treatments for obesity and should not be used to achieve weight loss. Under no circumstance should thyroxine be prescribed for obesity in the absence of biochemically proven hypothyroidism. There has been experimental interest recently about the effect of testosterone and growth hormone (GH) administration on visceral adipose tissue mass.
Men, with excessive abdominal fat, often have relatively low serum testosterone concentrations despite reduced levels of sex hormone binding globulin (SHBG). 35 Marin and colleagues 36 have demonstrated a signi®cant decrease in visceral fat mass and abdominal sagittal diameter in middle aged abdominally obese men, treated with eight months of oral testosterone supplements. This reduction occurred without a detectable change in subcutaneous fat. In addition, there was an improvement in plasma glucose disposal and increased insulin insensitivity. The authors concluded that such men have a relative hypogonadism and associated metabolic abnormalities, which are partly corrected by testosterone supplementation. Calculations of lipid uptake and LPL activity, using isotope labelling techniques, suggested diminished activity in abdominal adipose tissue but no change in femoral fat. 37, 38 The effects of testosterone were much more marked in visceral fat compared to subcutaneous abdominal fat because the uptake of lipid was inhibited by approximately 50% in the intra-abdominal tissues. This has been con®rmed by studies of lipid turnover in visceral adipose tissue from rats. 39 Thus, testosterone supplementation in obese men decreases uptake of lipid particularly in visceral fat and increases the rate of fat mobilisation.
Excessive fat deposition, predominantly on the trunk, is a feature of growth hormone de®ciency (GHD) in adults. Recent studies have shown that this is accompanied by excessive visceral fat accumulation. Boer and colleagues 40 have assessed the degree of subcutaneous and intra-abdominal fat accumulation in GHD men relative to that of age and sex-matched controls and evaluated the effects of long term GH treatment on subcutaneous and intra-abdominal fat. Measurements of skinfold thickness, waist and hip circumference and CAT scans at the midlevel of the fourth lumbar vertebra were taken before and after 12 months of GH treatment. Optimal GH treatment, which was de®ned as treatment resulting in the normalisation of serum insulin-like growth factor-1, resulted in a 27% decrease in the sum of skinfold thicknesses and a 47% reduction in intra-abdominal fat. Although the possible bene®ts of growth hormone treatment in obesity have been suggested from preliminary trials with GH in the past, it is unwise to extrapolate the results from the study of GHD patients to the obese patient. 41 The potential hazards of the use of testosterone and growth treatment in such a circumstance must be emphasised. Both hormones have marked lipolytic actions and will result in an even greater mobilisation of free fatty acids in obese subjects thereby enhancing the existing hyperinsulinaemia. This may lead to hyperglycaemia with worsening of the already deranged metabolic parameters. Growth hormone and testosterone supplements should not be regarded as treatment for upper body fat.
Serotoninergic drugs: dexfen¯uramine, which is a serotoninergic d isomer, was isolated from racemic fen¯uramine. Dexfen¯uramine has little effect on the dopaminergic system but increases presynaptic output of serotonin and decreases serotonin re-uptake by nerve terminals in the central nervous system. The weight lost on dexfen¯uramine would appear to involve fat loss although few studies have reported this parameter or evaluated whether dexfen¯uramine has speci®c actions on different fat tissue regions. O'Connor and colleagues 42 have investigated this in a study of 50 obese subjects [BMI 30±40 kg/m 2 ] over six months. They showed that the obese subjects treated with dexfen¯uramine lost 9.9 kg in weight of which 4.4 kg was calculated as fat using bio-electrical impedance measurements; the waist circumference decreased 10.5 cm. On placebo, weight loss was 4.6 kg of which only 1 kg was fat and the decrease in waist was only 5.7 cm. Interestingly, when the subjects were divided on the basis of body fat distribution, a similar percentage of weight loss as fat was observed for the group with upper body obesity (41.2%) and for those with lower body segment obesity (43%) irrespective of whether the subjects had been treated with dexfen¯uramine or placebo ( Table 2) . Moreover, the reduction in waist circumference did not differ signi®cantly between the dexfen¯uramine treated and placebo treated groups for comparable degrees of weight loss. A recent study of obese subjects treated with 12 weeks of dexfen¯ur-amine reported similar ®ndings using measurements of intra-abdominal fat from DEXA scanning. 43 These ®ndings once again con®rm that weight loss per se is the most important determinant of decreased intraabdominal fat. Importantly in the O'Connor study, the treated group had regained weight ®ve months after the cessation of dexfen¯uramine while the placebo group continued to lose weight, such that at the 11th month from the outset of the trial both groups had lost similar weight (6.0 kg vs 6.2 kg on placebo). This underlines the need for appropriate preventive measures to be included as part of the treatment programme to hinder weight regain.
Conclusions
Visceral adipose tissue within the abdomen engenders speci®c alterations in metabolic function as a consequence of a series of adverse processes which includes hyperinsulinaemia and altered sensitivity to catecholamines. Any treatment leading to an overall reduction in body fat will improve this situation or even reverse it. Thus, the practical answer to the original question about speci®c treatments for upper body fat must be: any treatment which reduces total body fat will be, by its nature, effective in reducing visceral abdominal fat. 
